Medicare GLP-1 drug pricing: Can it break even?
Explore whether Medicare can cover GLP-1 drugs without losing money if prices drop to the lowest rates negotiated by other developed nations.
In This Article▾
The Surprising Truth About Medicare, GLP-1 Drugs, and the Most Favored Nation Pricing Deal
Most people assume that cheaper drug prices automatically mean savings for Medicare. But the math behind Ozempic and Wegovy pricing is far more complicated than a simple discount can fix. In November 2025, the White House announced a sweeping "most favored nation" (MFN) policy that ties U.S. prices for GLP-1 receptor agonist drugs to what other wealthy countries pay. The big question nobody's really answering: can Medicare actually break even on these medications, even at those reduced prices?
Honestly, the answer is murky. And the details matter a lot.
Editor's Pick
We Tested Dozens. These 5 Actually Work.
After months of research and real-world testing, we put together a no-fluff ranking of the most effective supplements in this category for men over 40.
See Our Top 5 Picks →What the Most Favored Nation Policy Actually Does
The MFN policy is straightforward in concept. The U.S. has historically paid dramatically more for brand-name drugs than countries like Germany, Canada, or Japan. So the idea is simple: match those lower international prices domestically.
For GLP-1 drugs specifically, this is a big deal. Ozempic (semaglutide) can cost over $900 per month without insurance in the U.S. In comparable wealthy nations, the same drug often costs under $100. That's not a small gap. That's a canyon.
The November 2025 deals brought manufacturers including Novo Nordisk and Eli Lilly to the table. Drugs like Ozempic, Wegovy, Mounjaro, and Zepbound were all part of the agreement. But here's the thing: a discounted price doesn't automatically translate into Medicare breaking even on coverage costs.
How MFN Pricing Gets Calculated
MFN pricing usually pegs U.S. drug costs to the cheapest rates among other wealthy countries. Think of it as a comparison with places like those in the OECD with strong healthcare systems. So basically, the U.S. price gets capped or matched to that lower figure.
In reality, drug companies haggle over these prices with each country separately. So, the "most favored" price isn't just one set number. It's kind of a moving target. And let's be real, manufacturers have always been pretty crafty, using rebates and tiered pricing to maneuver around it.
Why Manufacturers Agreed This Time
To be fair, this wasn't purely altruistic. Manufacturers faced increasing political pressure, potential legislative action, and the real threat of Medicare being empowered to negotiate prices directly under the Inflation Reduction Act. Accepting MFN pricing, at least for GLP-1s, may have been the better deal for industry compared to what could have come next.
Can Medicare Actually Break Even? The Real Numbers
Here's where things get genuinely complicated. Medicare's ability to break even on GLP-1 drugs depends on at least three separate factors: the negotiated price per prescription, the volume of eligible patients, and whether the clinical benefits reduce other Medicare spending over time.
The volume issue alone is staggering.
An estimated 40% of American adults qualify as obese, and tens of millions more have type 2 diabetes, which is the original approved indication for semaglutide. If Medicare covers Wegovy broadly for obesity treatment, the sheer number of beneficiaries using it could make even a heavily discounted price fiscally challenging.
The Offset Argument: Do GLP-1 Drugs Save Money Elsewhere?
Supporters of broad GLP-1 coverage argue that these drugs reduce costly downstream conditions. Research published through the New England Journal of Medicine found that semaglutide reduced the risk of major cardiovascular events by 20% in people with obesity but without diabetes. That kind of outcome could theoretically lower Medicare spending on heart attacks, strokes, and related hospitalizations.
So the offset argument has real merit. But it also assumes patients stay on the medication long term, which is expensive, and that the cardiovascular savings are large enough to compensate for the drug costs. That math hasn't been fully validated at scale yet.
What Independent Budget Analysts Are Saying
The Congressional Budget Office and health economists have been sounding the alarm. Even with MFN discounts, covering GLP-1 drugs broadly for Medicare's obesity patients could run up a tab of hundreds of billions over ten years. Some say MFN pricing might chop that burden down by 40 to 60 percent. That's actually not nothing. But let's be honest, it's still not a break-even deal.
I'll be honest: the framing of "breaking even" may be the wrong lens entirely. Medicare rarely breaks even on any individual drug category. The question is whether the clinical value justifies the public investment.
What This Means for Patients Right Now
If you're currently taking Ozempic or Wegovy, or hoping to access them through Medicare, the MFN policy is a step in the right direction. Prices should come down. Access may improve. But this isn't a solved problem.
Coverage gaps still exist. Medicare Part D didn't historically cover weight loss drugs, and while that's been changing, the rollout is uneven. Even with lower list prices, out-of-pocket costs for many beneficiaries remain a real barrier.
According to information from the official Medicare drug coverage program, individual plan formularies vary significantly, meaning the same drug can have very different cost-sharing depending on which plan a person is enrolled in.
And straight up, that inconsistency is a policy failure that pricing deals alone won't fix.
The Bigger Picture for GLP-1 Policy
The MFN pricing move is a big hint: the U.S. government is finally flexing a bit to push drug prices closer to what other countries pay. It's a meaningful shift, even if we might be twiddling our thumbs waiting for it to really kick in.
But GLP-1 drugs represent a unique stress test for the healthcare system. They work. They're popular. And the patient population that could benefit from them is enormous. Getting the pricing right isn't just a budget exercise. It's a question of how the country wants to address chronic disease at a systemic level.
Frequently Asked Questions
What is the most favored nation pricing policy for GLP-1 drugs?
The most favored nation (MFN) policy links U.S. drug prices to the lowest rates other rich countries pay. For GLP-1 drugs like Ozempic and Wegovy, the White House cut deals in November 2025 with companies like Novo Nordisk and Eli Lilly. The goal? Bringing our prices closer to international ones, which are often 70 to 90 percent cheaper than what we're paying now.
Will Medicare cover Wegovy and Ozempic after the MFN deal?
Medicare coverage of Wegovy and Ozempic varies by plan and indication. Ozempic has long been covered for type 2 diabetes management, but Wegovy for obesity has faced more inconsistent coverage. The MFN pricing deal may accelerate broader coverage decisions, but individual Part D plans still determine their own formularies.
Can lower GLP-1 drug prices actually save Medicare money?
Sure, but don't count on it. MFN pricing chops down per-unit costs a lot. And there's research saying these drugs might lower heart risks. That could help with some Medicare bills later on. But whether the savings beat the costs? That all hinges on how many folks use 'em, if they stick with 'em, and how wide we open up coverage.
How do GLP-1 drugs like Ozempic work for weight loss?
GLP-1 receptor agonists mimic a natural hormone that regulates appetite and blood sugar. They slow gastric emptying and signal fullness to the brain, reducing cal
James Carter is the lead reviewer at Men Vitality Hub. For the past decade he has researched men's health supplements, digging through ingredient studies, real buyer feedback and refund policies so readers can decide with confidence. Every review follows the same process: published research, verified user reports and hands-on price checking.